Adsan H, Tulunay M, Onaran O
Department of Anesthesiology and Reanimation, Ankara University Medical School, Turkey.
Anesth Analg. 1998 Apr;86(4):818-24. doi: 10.1097/00000539-199804000-00026.
The purpose of this in vivo and in vitro study was to compare the effects of verapamil or nimodipine pretreatment on bupivacaine-induced cardiotoxicity. In the in vivo study, the dose-response curve for the 50% lethal dose (LD50) of bupivacaine was determined for rats. Two separate groups of rats were pretreated with i.v. verapamil 150 microg/kg (n = 35) or i.v. nimodipine 200 microg/kg (n = 35). Each pretreatment group was then subdivided into four groups of at least four rats each. Three minutes after pretreatment, bupivacaine was administered to each of four groups in doses of 2.5, 3.0, 3.25, and 3.5 mg/kg, respectively. Both verapamil and nimodipine pretreatment increased the LD50 and 95% confidence intervals for bupivacaine and increased survival. In the in vitro study, the effects of verapamil or nimodipine perfusion on bupivacaine cardiotoxicity (negative chronotropic, negative inotropic, and arrhythmogenic effects) and coronary perfusion pressure (CPP) were investigated in isolated, perfused rat heart preparations. Depression of heart rate, contractile force, and CPP, and the incidence of arrhythmias caused by bupivacaine alone were similar to those caused by bupivacaine after verapamil pretreatment. In contrast, bupivacaine induced less negative chronotropic effects (P < 0.05, paired t-test) and arrhythmias (P < 0.05, chi2 analysis) after nimodipine pretreatment. The results of this study demonstrate that both verapamil and nimodipine pretreatment decrease bupivacaine-induced cardiotoxicity in vivo, whereas only nimodipine pretreatment decreased bupivacaine-induced cardiotoxicity and arrhythmias in vitro.
In this experimental study consisting of two stages (in vivo and in vitro), we compared the effects of two calcium channel-blocking drugs (verapamil and nimodipine) on bupivacaine toxicity. Bupivacaine is a local anesthetic frequently used in clinical practice, and cardiotoxicity is one of its severe side effects. Verapamil and nimodipine were both effective in decreasing bupivacaine cardiotoxicity in this rat model.
本体内和体外研究的目的是比较维拉帕米或尼莫地平预处理对布比卡因所致心脏毒性的影响。在体内研究中,测定了布比卡因对大鼠的半数致死剂量(LD50)的剂量 - 反应曲线。将两组不同的大鼠分别用静脉注射维拉帕米150μg / kg(n = 35)或静脉注射尼莫地平200μg / kg(n = 35)进行预处理。然后将每个预处理组再细分为至少每组四只大鼠的四组。预处理三分钟后,分别以2.5、3.0、3.25和3.5mg / kg的剂量向四组中的每组大鼠给予布比卡因。维拉帕米和尼莫地平预处理均增加了布比卡因的LD50及95%置信区间,并提高了生存率。在体外研究中,在离体灌注大鼠心脏标本中研究了维拉帕米或尼莫地平灌注对布比卡因心脏毒性(负性变时性、负性变力性和致心律失常作用)及冠状动脉灌注压(CPP)的影响。单独使用布比卡因引起的心率、收缩力和CPP降低以及心律失常发生率与维拉帕米预处理后布比卡因引起的相似。相比之下,尼莫地平预处理后布比卡因引起的负性变时性作用(配对t检验P < 0.05)和心律失常(χ2分析P < 0.05)较少。本研究结果表明,维拉帕米和尼莫地平预处理均可降低布比卡因在体内所致的心脏毒性,而仅尼莫地平预处理可降低布比卡因在体外所致的心脏毒性和心律失常。
在这个由两个阶段(体内和体外)组成的实验研究中,我们比较了两种钙通道阻滞剂(维拉帕米和尼莫地平)对布比卡因毒性的影响。布比卡因是临床实践中常用的局部麻醉药,心脏毒性是其严重副作用之一。在这个大鼠模型中,维拉帕米和尼莫地平均能有效降低布比卡因的心脏毒性。